



Participant Information Statement

Research study: Lancet Ovarian Cancer Commission – Clinician Survey

1. What is this study about?

This study is open internationally to clinicians involved in the care of women with ovarian cancer. It will address important knowledge gaps about ovarian cancer care around the world, future developments in treatment and in supportive care. We will ask you about:

- prevention practices and managing risk;
- ovarian cancer management;
- your preferences and priorities regarding new ovarian cancer therapies; the information you provide about ovarian cancer to your patients and how that could be improved in the future
- supportive care for managing the physical and emotional side-effects of ovarian cancer and how that could be improved in the future
- your willingness to engage with new developments in digital health for example web-based followup and use of artificial intelligence (AI) to support better personalised care, monitoring and control of symptoms.

Thank you for your participation. Your views are very important and will help shape recommendations for the future of ovarian cancer treatment and care.

2. Who is running this study?

This survey is being conducted by the Lancet Commission on Ovarian Cancer. This study is being conducted as part of a larger initiative of The Lancet Ovarian Cancer Commission to document how ovarian cancer prevention, diagnosis, treatment and supportive care are delivered across different health systems, and where the largest gaps in access lie.

The Lancet Ovarian Cancer Commission brings together international clinical and scientific experts as well as patient advocates to review evidence, identify new opportunities to make progress, and make a series of recommendations that will help shape global and national health agendas and drive positive, equitable, change for all.

This survey is being led by the following researchers:

- Dr Rebecca Mercieca-Bebber, Sydney Clinical Trials Centre, The University of Sydney, Australia.
- Professor Martin Stockler, Sydney Clinical Trials Centre, The University of Sydney, Australia.



- Annwen Jones OBE, World Ovarian Cancer Coalition, United Kingdom. Chair, Lancet Ovarian Cancer Commission Patient Advisory Board.
- Dr Laura Venegas, Gynecological Malignancies/ Drug Development Program, Princess Margaret Cancer Center, Toronto Canada.
- Professor Florence Joly, Medical Oncology department, Centre François Baclesse, Unicaen University, Inserm U1086, Caen, GINECO Intergroup, France.
- Associate Professor Joyce Liu, Dana Farber Cancer Institute (DFCI) and Harvard Medical School, Massachusetts, USA.
- Dr Assima Mukhopadhyay, Tata Medical Centre, Kolkata, India.
- Professor Ranjit Manchanda, Wolfson Institute of Population Health, Queen Mary University of London, UK.
- Professor Don Dizon, Tufts Medical Center Hematology Oncology, Boston, MA, USA.
- Associate Professor Celeste Leigh Pearce, University of Michigan, USA.
- Professor Jonathan A. Ledermann, UCL Cancer Institute, University College London, London, United Kingdom
- Professor Kathleen Moore, University of Oklahoma Health Sciences Center, Oklahoma USA.
- Professor Isabelle Ray-Coquard, Centre Leon Bérard, Université Claude Bernard Lyon Est, Lyon France.

This study is being funded by Centre Leon Berard, Lyon, France. Our supporters include: Centre Leon Berard, Lyon, France; Arcagy GINECO; National University Cancer Institute Singapore; Foundation for Women's Cancer; World Ovarian Cancer Coalition; Tufts Medicine; Society of Gynecologic Oncology; UHN Princess Margaret Cancer Centre; European Society of Gynaecological Oncology (ESGO); Ovarian Cancer Research Alliance; BC Cancer Foundation; GOG Foundation; Tina's Wish; Women's Precision Prevention Department of Gynaecological Oncology Barts Health NHS Trust; Centre Baclesse Univancer Normandie Caen; Fondazione Humanitas Ricerca; The University of Sydney. No commercial or pharmaceutical funding has been received.

3. Who can take part in the study?

You are eligible to participate if you are a qualified physician in gynaecological oncology, gynaecology, medical oncology, radiation oncology, clinical oncology, surgery, clinical genetics, genetics counselling; or oncology nurse:

- currently treating ovarian cancer,



- with at least 12 months experience treating ovarian cancer,
- able to provide informed consent,
- able to complete the survey in English.

4. What will the study involve for me?

If you choose to take part, you will provide your consent to participate on the first page of the online survey. You will then answer a series of questions about ovarian cancer care.

You can complete the survey online using your computer, phone or tablet. You only need to complete the survey **once**. It should take approximately <40- minutes to complete.

There are no right or wrong answers, we are simply interested in your views. Unless a question specifies otherwise, please answer for the institution where you spend most of your clinical time, and give your best estimate where exact figures are not available.

Your responses will be anonymous and confidential.

5. Can I withdraw once I have started?

Participation is completely voluntary and you do not have to take part. **You can stop and exit the survey at any time.** We will not be able to withdraw your data after you have started the survey, because the survey is anonymous and we will not be able to determine which responses belong to you.

6. Are there any risks or costs?

The survey will take up approximately <40 minutes of your time.

There are no risks or costs associated with participating in this survey.

7. Are there any benefits?

You will not receive any direct benefits from being in the study.

8. What will happen to information that is collected?

The data you provide in this survey will be securely stored at the University of Sydney, Australia. The survey results will be published in a medical journal and presented at conferences. You will not be identifiable in these publications or presentations because all survey data is anonymous. The anonymous survey data may be used for future research studies upon approval of the research team.



9. Will I be told the results of the study?

The study findings will be published by the Lancet Ovarian Cancer Commission in academic journals, presented at scientific conferences and the Lancet Ovarian Cancer Commission networks. What if I would like more information?

For any questions or further discussions, please contact: health-outcomes.ctc@sydney.edu.au and you will receive a response within 5 business days.

10. What if I have a complaint or any concerns?

The ethical aspects of this study have been approved by the Human Research Ethics Committee (HREC) [ethics identifier 2006/HE000512] according to the National Statement on Ethical Conduct in Human Research.

If you have any concerns about the study procedures or would like to make a complaint to someone not involved in the study, please contact health-outcomes.ctc@sydney.edu.au and you will receive a response within 5 business days.